Awaiting a billion-dollar deal
Another cancer tech player that McDonald holds is Immutep Ltd (ASX: IMM).
Its share price has halved since November, giving it a current market capitalisation of around $310 million.
With the company targeting a US$50 billion addressable market in breast, lung, head & neck cancer markets, McDonald is convinced Immutep is undervalued.
“Similar biotech deals, either licensing or takeover, would probably be in the US$2 to US$5 billion range. So very substantial upside.”
Immutep has been granted a “prestigious” oral presentation at the American Society of Clinical Oncology conference on 3 June.
“It’s the largest healthcare conference in the world,” said McDonald.
“We can only assume it’s very good news… We’re greatly looking forward to that.”
Awaiting a billion-dollar dealAnother cancer tech player that...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |